Full-Time

Senior Software Engineer

Posted on 2/11/2025

Formation Bio

Formation Bio

51-200 employees

Accelerates drug development using AI technology

Compensation Overview

$180k - $230k/yr

+ Equity + Generous Perks

Senior

New York, NY, USA

NYC-based employees are expected to work in the office at least two days per week. All employees located outside of the NYC Metro Area will be expected to travel to the NYC office at least four times per year for company events and team-specific meetings or activities.

Category
Backend Engineering
Full-Stack Engineering
Software Engineering
Required Skills
LLM
Microsoft Azure
AWS
Google Cloud Platform
Requirements
  • Bachelor’s or Master’s degree in Computer Science, Engineering, or a related field, or equivalent experience.
  • Minimum of 6 years of experience in software development, with a demonstrated ability to thrive in ambiguous and rapidly-changing environments, with a proven track record of contributing significantly to the successful launch and scaling of new and innovative products, especially in a 0-1 setting.
  • Exceptional collaboration and communication skills to effectively engage and work alongside stakeholders from diverse disciplines and varying levels of technical expertise. Ideally, adept at translating complex technical concepts into clear, actionable insights for all audiences.
  • Familiarity with cloud infrastructure (e.g., AWS, Azure, GCP) and the full end-to-end process of modern software deployment (e.g., containerization, CI/CD).
Responsibilities
  • Lead the design, development, and deployment of software solutions that leverage AI and LLM technologies in the strategic drug development process.
  • Collaborate with cross-functional teams, including product managers and domain experts, to discover, build, and iterate on products and tools to empower our users.
  • Ensure the scalability, security, and performance of our software systems in a cloud-based user-focused environment.
  • Rapidly develop and iterate on product deliverables in alignment with strategic objectives in drug development.
  • Stay abreast of emerging trends and advancements in AI, LLMs, and software development to continually enhance our product offerings.
  • Act as an internal evangelist for use of AI and LLMs, providing expert guidance and insights to other teams within the organization.
Desired Qualifications
  • Experience with AI technologies particularly in LLMs and machine learning is a plus, but not required.
  • Experience in the pharmaceutical or biotech industry is a plus, but not required.

Formation Bio focuses on speeding up the process of developing new drugs by using its own AI-driven platform. This platform helps the company identify and acquire clinical-stage assets, which are drugs that are already in testing phases. By using flexible financing options, Formation Bio aims to lower the costs and time it usually takes to bring new medications to market. This makes it easier for pharmaceutical and biotech companies to develop drugs more quickly and affordably. Unlike many competitors, Formation Bio emphasizes the use of advanced AI tools to improve drug selection and development efficiency. The ultimate goal of the company is to make new treatments more accessible to patients by successfully commercializing drugs and forming partnerships.

Company Size

51-200

Company Stage

Series D

Total Funding

$530.3M

Headquarters

New York City, New York

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • $372M Series D funding boosts platform expansion and asset acquisition capabilities.
  • Collaboration with OpenAI and Sanofi advances AI-driven drug discovery standards.
  • Precision genomics partnership with SomaLogic improves biomarker identification and patient stratification.

What critics are saying

  • Competition from other AI-driven drug developers may impact market share.
  • Regulatory scrutiny on AI processes could lead to delays and compliance costs.
  • Dependence on partnerships poses risks if collaborations dissolve or underperform.

What makes Formation Bio unique

  • Formation Bio uses AI to accelerate drug development, reducing costs and timelines.
  • The company acquires clinical-stage assets, enhancing drug development flexibility and efficiency.
  • Partnerships with major pharma firms provide access to proprietary data and resources.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

-1%
Intelligence360
Jul 18th, 2024
Trialspark Dba Formation Bio Has Filed A Notice Of An Exempt Offering Of Securities To Raise $372,000,000.00 In New Equity Investment.

TrialSpark dba Formation Bio has filed a notice of an exempt offering of securities to raise $372,000,000.00 in New Equity Investment. TrialSpark dba Formation Bio has filed a notice of an exempt offering of securities to raise $372,000,000.00 in New Equity Investment.According to filings with the U.S. Securities and Exchange Commission, TrialSpark dba Formation Bio is raising up to $372,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Benjamine Liu played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.About TrialSpark dba Formation BioFormation Bio is a tech-driven pharmaceutical company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. The company acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop them faster in order to accelerate access to new treatments for patients, and to unlock greater value per program.To learn more about TrialSpark dba Formation Bio, visit http://www.formation.bio/TrialSpark dba Formation Bio Linkedin Page: https://www.linkedin.com/company/formationbio/Contact:Benjamine Liu, Chief Executive Officer866-283-7544https://www.linkedin.com/in/benjamine-liu-54306518/SOURCE: http://www.intelligence360.ioCopyright (c) 2024 SI360 Inc

Finsmes
Jun 26th, 2024
Formation Bio Raises $372M in Series D Funding

Formation Bio, a NYC-based tech-driven and AI-native pharma company, raised $372M in Series D funding

Hit Consultant
May 21st, 2024
Sanofi, Formation Bio, Openai Partner On Ai-Powered Drug Discovery

What You Should Know:– Sanofi, a global pharmaceutical leader, Formation Bio, an AI-powered drug developer, and OpenAI, a leading research and development company in artificial intelligence, have announced a groundbreaking collaboration. The first-of-its-kind partnership in the pharma and life sciences industries aims to leverage AI to accelerate drug development and bring new medicines to patients faster.– Sanofi, Formation Bio, and OpenAI believe this collaboration will be a game-changer in the pharmaceutical industry. By combining their expertise in data, AI technology, and drug development, they aim to revolutionize the way new medicines are discovered and brought to market.A Symphony of ExpertiseThe collaboration will combine the unique strengths of each partner:Sanofi: Will contribute proprietary data for building custom AI models, furthering their goal of becoming the first biopharma company powered by AI at scale. This data will be crucial for training and refining the AI tools used in drug discovery.Will contribute proprietary data for building custom AI models, furthering their goal of becoming the first biopharma company powered by AI at scale. This data will be crucial for training and refining the AI tools used in drug discovery. OpenAI: World-renowned for its advancements in AI technology, OpenAI will contribute access to cutting-edge AI capabilities

PR Newswire
Jan 10th, 2022
Trialspark partners with SomaLogic, Inc.

TrialSpark is also partnering with industry leaders such as SomaLogic to leverage precision genomics and proteomics platforms to identify key biomarkers and stratify patients using synovial fluid samples from prior clinical studies using AI and machine-learning approaches.

CB Insights
Oct 5th, 2021
Trialspark partnered with SANOFI PASTEUR on Aug 6th 18'.

TrialSpark has collaborated with pharma companies such as Sanofi, Novartis, and Pfizer, among others.

INACTIVE